BLUE
Profile banner
MM
Michael Marks
@drmichaelmarks.bsky.social
Professor of Medicine at LSHTM. Lead for Integrated Academic Training at LSHTM. Consultant in Infectious Diseases at UCLH. Syphilis & STIs, Neglected Tropical Diseases, Emerging Infectious Diseases, Group A Strep, Pragmatic Trials
72 followers78 following6 posts
MMdrmichaelmarks.bsky.social

Different trials for each. There is a fairly worked up proposal for a "definitive treatment trial" but that can't easily get at Q's on empiric IVIG & anti-toxins. The latter much harder as syndromes caused by a range of bacteria some where interventions might help and some where we presume does zero

1

TYtomayates.bsky.social

Fair enough, but presumably more efficient to nest the IVIG/anti-toxin randomisation within an existing definitive treatment trial?

1
Profile banner
MM
Michael Marks
@drmichaelmarks.bsky.social
Professor of Medicine at LSHTM. Lead for Integrated Academic Training at LSHTM. Consultant in Infectious Diseases at UCLH. Syphilis & STIs, Neglected Tropical Diseases, Emerging Infectious Diseases, Group A Strep, Pragmatic Trials
72 followers78 following6 posts